These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1400 related items for PubMed ID: 31141284

  • 1. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 2. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

  • 3. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 4. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
    Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L.
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [Abstract] [Full Text] [Related]

  • 6. Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Reyhan M, Tuncel M, Akyol F.
    Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
    [Abstract] [Full Text] [Related]

  • 7. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
    Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, Shariat SF, Montorsi F, Briganti A.
    Eur Urol Oncol; 2024 Apr; 7(2):231-240. PubMed ID: 37689506
    [Abstract] [Full Text] [Related]

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Apr; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 9. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 10. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (68 Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection.
    Huits TH, Luiting HB, van der Poel HG, Nandurkar R, Donswijk M, Schaake E, Vogel W, Roobol MJ, Wit E, Stricker P, Emmett L, van Leeuwen PJ.
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [Abstract] [Full Text] [Related]

  • 11. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

  • 12. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 13. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 14. The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy.
    Raveenthiran S, Yaxley J, Gianduzzo T, Kua B, McEwan L, Wong D, Tsang G, MacKean J.
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
    [Abstract] [Full Text] [Related]

  • 15. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV, Campobasso D, Guarino G, Acampora A, Scarlattei M, Ziglioli F, Dinale F, Baldari G, Migliari S, Gasparro D, Ferretti S, Silini EM, Ruffini L.
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [Abstract] [Full Text] [Related]

  • 16. The role of histopathological and biochemical parameters for predicting metastatic disease on 68 Ga-PSMA-11 PET in prostate cancer.
    Aydos U, Çetin S, Akdemir ÜÖ, Budak FÇ, Ateş SG, Koparal MY, Gönül İI, Gülbahar Ö, Sözen S, Atay LÖ.
    Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677
    [Abstract] [Full Text] [Related]

  • 17. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology.
    Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [Abstract] [Full Text] [Related]

  • 18. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
    Esen T, Falay O, Tarim K, Armutlu A, Koseoglu E, Kilic M, Seymen H, Sarikaya AF, Kiremit MC, Balbay MD, Canda AE, Baydar DE, Kordan Y, Demirkol MO, Tilki D.
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [Abstract] [Full Text] [Related]

  • 19. The diagnostic accuracy of 68 Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis.
    Rajwa P, Heidenreich J, Drzezga A, Schmidt M, Shariat SF, Heidenreich A.
    Prostate; 2024 Jan; 84(1):74-78. PubMed ID: 37750292
    [Abstract] [Full Text] [Related]

  • 20. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
    Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, Geboers B, Agrawal S, Siriwardana A, Van Leeuwen PJ, van Oosterom MN, Van Leeuwen FWB, Emmett L, Stricker PD.
    J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.